Magnetic resonance imaging of the breast: Opportunities to improve breast cancer management

Journal of Clinical Oncology

Volumn 23, Issue 8, 2005, Pages 1678-1684

  Hylton, Nola ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BREAST CANCER; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC IMAGING; GEOGRAPHIC DISTRIBUTION; HISTOPATHOLOGY; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; BREAST TUMOR; FEMALE; ISOLATION AND PURIFICATION; METHODOLOGY; PAGET NIPPLE DISEASE; PATHOLOGY; RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; TUMOR MARKERS, BIOLOGICAL;

EID: 15544387615     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.002     Document Type: Review

References (54)

1. Nakahara H, Namba K, Fukami A, et al: Three-dimensional MR imaging of mammographically detected suspicious microcalcifications. Breast Cancer 8:116-124, 2001
2. Trecate G, Tess JD, Vergnaghi D, et al: Breast microcalcifications studied with 3D contrast-enhanced high-field magnetic resonance imaging: More accuracy in the diagnosis of breast cancer. Tumori 88:224-233, 2002
3. Gilles R, Meunier M, Lucidarme O, et al: Clustered breast microcalcifications: Evaluation by dynamic contrast-enhanced subtraction MRI. J Comput Assist Tomogr 20:9-14, 1996
4. Westerhof JP, Fischer U, Moritz JD, et al: MR imaging of mammographically detected clustered microcalcifications: is there any value? Radiology 207:675-681, 1998
5. Holland AE, Hendrick RE, Jin H, et al: Correlation of high-resolution breast MR imaging with histopathology: Validation of a technique. J Magn Reson Imaging 11:601-606, 2000
6. James D, Clymer BD, Schmalbrock P: Texture detection of simulated microcalcification susceptibility effects in magnetic resonance imaging of breasts. J Magn Reson Imaging 13:876-881, 2001
7. Heywang SH, Wolf A, Pruss E, et al: MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 171:95-103, 1989
8. Kaiser WA, Zeitler E: MR imaging of the breast: Fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 170:681-686, 1989
9. Orel SG, Schnall MD, Powell CM, et al: Staging of suspected breast cancer: Effect of MR imaging and MR-guided biopsy. Radiology 196:115-122, 1995
10. Stomper PC, Herman S, Klippenstein DL, et al: Suspect breast lesions: Findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 197:387-395, 1995
11. Gilles R, Guinebretiere JM, Lucidarme O, et al: Nonpalpable breast tumors: Diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 191:625-631, 1994
12. Boetes C, Mus RD, Holland R, et al: Breast tumors: Comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 197:743-747, 1995
13. Harms SE, Flamig DP, Hesley KL, et al: MR imaging of the breast with rotating delivery of excitation off resonance: Clinical experience with pathologic correlation. Radiology 187:493-501, 1993
14. Kriege M, Brekelmans CT, Boetes C, et al: Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427-437, 2004
15. Leach MO, Eeles RA, Turnbull LW, et al: The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). J Exp Clin Cancer Res 21:107-114, 2002 (suppl 3)
16. Warner E, Plewes DB, Hill KA, et al: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317-1325, 2004
17. Kuhl CK, Schmutzler RK, Leutner CC, et al: Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results. Radiology 215:267-279, 2000
18. Morris EA, Liberman L, Ballon DJ, et al: MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 181:619-626, 2003
19. Mumtaz H, Hall-Craggs MA, Davidson T, et al: Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 169:417-424, 1997
20. Van Goethem M, Schelfout K, Dijckmans L, et al: MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: Comparison with mammography and ultrasound. Eur Radiol 14:809-816, 2004
21. Henry-Tillman RS, Harms SE, Westbrook KC, et al: Role of breast magnetic resonance imaging in determining breast as a source of unknown metastatic lymphadenopathy. Am J Surg 178:496-500, 1999
22. Orel SG, Weinstein SP, Schnall MP, et al: Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 212:543-549, 1999
23. Schorn C, Fischer U, Luftner-Nagel S, et al: MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol 9:470-473, 1999
24. Tilanus-Linthorst MM, Obdeijn Al, Bontenbal M, et al: MRI in patients with axillary metastases of occult breast carcinoma. Breast Cancer Res Treat 44:179-182, 1997
25. Schelfout K, Kersschot E, Van Goethem M, et al: Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy. Eur Radiol 13:2128-2132, 2003
26. Chen C, Orel SG, Harris E, et al: Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 5:72-77, 2004
27. Gilles R, Guinebretiere JM, Shapeero LG, et al: Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 188:473-478, 1993
28. Melani E, Sardanelli F, Ottonello C, et al: Magnetic resonance mammography in suspected tumor recurrences. Radiol Med (Torino) 89:219-224, 1995
29. Muuller RD, Barkhausen J, Sauerwein W, et al: Assessment of local recurrence after breast-conserving therapy with MRI. J Comput Assist Tomogr 22:408-412, 1998
30. Whitehouse GH, Moore NR: MR imaging of the breast after surgery for breast cancer. Magn Reson Imaging Clin N Am 2:591-603, 1994
31. Soderstrom CE, Harms SE, Copit DS, et al: Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology 201:427-432, 1996
32. Esserman L, Hylton N, Yassa L, et al: Utility of magnetic resonance imaging in the management of breast cancer: Evidence for improved preoperative staging. J Clin Oncol 17:110-119, 1999
33. Bedrosian I, Mick R, Orel SG, et al: Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 98:468-473, 2003
34. Boetes C, Strijk SP, Holland R, et al: False-negative MR imaging of malignant breast tumors. Eur Radiol 7:1231-1234, 1997
35. Orel SG, Mendonca MH, Reynolds C, et al: MR imaging of ductal carcinoma in situ. Radiology 202:413-420, 1997
36. Sittek H, Kessler M, Heuch AF, et al: Morphology and contrast enhancement of ductal carcinoma in situ in dynamic 1.0 T MR mammography. Rofo 167:247-251, 1997
37. Zuiani C, Francescutti GE, Londero V, et al: Ductal carcinoma in situ: Is there a role for MRI? J Exp Clin Cancer Res 21:89-95, 2002 (suppl 3)
38. Hata T, Takahashi H, Wanatabe K, et al: Magnetic resonance imaging for preoperative evaluation of breast cancer: A comparative study with mammography and ultrasonography. J Am Coll Surg 198:190-197, 2004
39. Harms SE, Flamig DP: MR imaging of the breast: Technical approach and clinical experience. Radiographics 13:905-912, 1993
40. Liberman L, Morris EA, Lee MJ, et al: Breast lesions detected on MR imaging: Features and positive predictive value. AJR Am J Roentgenol 179:171-178, 2002
41. Hwang ES, Kinkel K, Esserman LJ, et al: Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: Value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol 10:381-388, 2003
42. Esserman L, Wolverton D, Hylton N: Magnetic resonance imaging for primary breast cancer management: Current role and new applications. Endocr Relat Cancer 9:141-153, 2002
43. Burstein HJ, Polyak K, Wong JS, et al: Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441, 2004
44. Esserman L, Sepucha K, Ozanne E, et al: Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol 11:28S-36S, 2004 (suppl 1)
45. Gilles R, Zafrani B, Guinebretiere JM, et al: Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 196:415-419, 1995
46. Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998
47. Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr:96-102, 2001
48. Partridge SC, Gibbs JE, Lu Y, et al: Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179:1193-1199, 2002
49. Esserman L, Kaplan E, Partridge S, et al: MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 8:549-559, 2001
50. Wasser K, Klein SK, Fink C, et al: Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution. Eur Radiol 13:80-87, 2003
51. Knopp MV, Brix G, Junkermann HJ, et al: MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am 2:633-658, 1994
52. Hayes C, Padhani AR, Leach MO: Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15:154-163, 2002
53. Martincich L, Montemurro F, De Rosa G, et al: Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83:67-76, 2004
54. Partridge SC, Gibbs JE, Lu Y, et al: MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol: in press